Day 1

Wednesday, March 3

Day 2

Thursday, March 4

Plenary Moderator: Jerome Rossert, Vice President, Head of Clinical Renal, AstraZeneca

8:10 am Chair’s Opening Remarks: The Value Proposition of Early Identification & Intervention of Kidney Disease

What’s Next? Opportunities for Additional Drug Development & Addressing Multiple Areas with Treatment

8:30 am Interplay Between Diabetes, Heart failure & CKD: What Can we Learn from Novel Drug Development?

  • Jyothis George Vice President, Clinical, Medical & Regulatory, Novo Nordisk

9:00 am Remaining Unmet Medical Need in Chronic Kidney Disease: Challenges & Opportunities for Additional Drug Development

9:30 am Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:

  • Uptal Patel Head of Clinical Renal, Early CVRM, AstraZeneca
  • Jyothis George Vice President, Clinical, Medical & Regulatory, Novo Nordisk
  • Richard Nkulikiyinka VP, Head of Therapeutic Area Cardiology & Nephrology, Bayer Pharmaceuticals
  • Sibylle Hauske Senior Medical Director & Global Clinical Development Lead - Empagliflozin in CKD, Boehringer Ingelheim

10:00 am What the Extracellular Matrix Tells us – Prognostic & Pharmacodynamic Biomarkers for Kidney Fibrosis in CKD

10:15 am Speed Networking

10:45 am Morning Break & Networking

Translational Drug Development Track

Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, AstraZeneca

Accessing & Interrogating Data to Inform Drug Target Discovery

11:15 am Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification

  • Wenjun Ju Associate Research Scientist of Internal Medicine, University of Michigan

11:45 am Next-generation Analysis of Kidney Tissue by Super-resolution Microscopy

  • Nicole Endlich Chief Executive Officer ; Professor University , NIPOKA, Medicine Greifswald

Disease Modeling for More Predictive Translation & Mechanistic Discovery

12:00 pm Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity

  • Beno Freedman Assistant Professor, Nephrology, University of Washington

12:30 pm Bioengineering Technologies to Model Renal Systems

  • Jonathan Himmelfarb Director of the Kidney Research Institute & Professor of Medicine, University of Washington

Clinical Drug Development Track


Track Moderator: Kevin Fowler, President, The Voice of the Patient

Considerations & Tools to Inform Clinical Decisions & Success

11:15 am Biomarkers as Key Drug Development Tools

11:45 am 15 minute Break

12:00 pm From Diagnostic to Therapeutic Targets

12:30 pm Renal Function Surrogates for Trial Endpoints & Clinical Decision Support: Are we Reshuffling an Old Deck or Adding New Cards to the Table?

  • Joe Stavas Senior Vice President of Clinical Development, ProKidney

1:00 pm Lunch Break

1:45 pm Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems

  • Josh Tarnoff Chief Executive Officer, NephCure Kidney International
  • Uptal Patel Head of Clinical Renal, Early CVRM, AstraZeneca
  • Jeff Hafkin Senior Director , Otsuka Pharmaceuticals

Implementing Precision Medicine in Renal Disease Studying Genetic Drivers & Targetable Mutations in Chronic Kidney Disease

Plenary Moderator: Michael Boettger, Head of Clin. Exp. CV, Translational Medicine, Bayer, Research & Development, Pharmaceuticals

2:15 pm Pathway Driven Patient Stratification in Glomerular Disease: A Report From the Trenches

  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan

2:45 pm Panel Discussion: Executing Precision Medicine in Clinical Trials

  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan
  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio
  • Jeremy Duffield Chief Scientific Officer, Prime Medicine
  • Andrew King Head of Renal Discovery & Translational Medicine, Chinook Therapeutics
  • Maria Gomez Professor of Physiology Head, Diabetic Complications Unit Director , Lund University Diabetes Centre (LUDC)

3:15 pm Afternoon Break

4:00 pm APOL1 – A Genetic Driver of Kidney Disease: From Concept to Clinical Trials

4:30 pm Targeting FSGS as an Entry Point in CKD: Expanding From a Smaller Market

  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio

5:00 pm Chair’s Closing Remarks

Click Here To See Day 2